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The aim of the study was to assess compliance with nasal continuous positive airway pressure (N-CPAP) at home in
patients with obstructive sleep apnoea syndrome (OSAS) and to search for predictors of compliance. We studied a
cohort of 106 consecutive patients (91 men, 15 women) with a median apnoea hypopnoea index of 624 (range 21–
132) h71, equipped at home with a Rem+ Soft device (Sefam, France), including a pressure monitor and a real-time
clock. During the third and fourth months of treatment, the patients used their machine a median of 88% of days
(16–100%), with a mean eective use of 56 (13–112) h per eective day. Residual apnoea index on N-CPAP, as
recorded by the monitor, was 15 (03–276) h71. Mean clock-time for starting with N-CPAP was 23 h 54 min (21 h
34–01 h 42). The mean eective use per eective day correlated negatively with the minimal (and the mean) level of
oxyhaemoglobin saturation (rs=7024, P5 005) while the percentage of days the machine was used correlated
negatively with the percentage of slow wave sleep (rs=7022, P5 005) at baseline polysomnography. In a subset
of 30 subjects, earlier start on N-CPAP correlated with longer use of the device in 22 patients (median r7048). We
conclude that a pressure monitor allows reporting on compliance in terms of regularity (% of days the machine is
used) and length of sleep on N-CPAP (eective use per eective day). These compliance variables show modest
correlations with baseline polysomnographic features. Late bedtime should be discouraged as it might decrease
compliance.
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Nasal continuous positive airway pressure (N-CPAP) is
often spectacularly eective in patients with obstructive
sleep apnoea syndrome (OSAS) when used as an acute trial
in the sleep laboratory. However, its ecacy as main-
tenance therapy at home is critically dependent on the
patient’s willingness to use the device and apply the nasal
mask during sleep. Adherence to N-CPAP can be
characterized (1) as the proportion of patients accepting
an acute trial in the sleep laboratory, followed by a trial of
such a treatment at home (primary acceptance), the
proportion of patients who pursue domiciliary N-CPAP
in the long-term (secondary acceptance) and the rate at
which patients who accept N-CPAP eectively use it
(compliance). Compliance can be assessed from self-report
by the patients, from reading the built-in time-counter ofReceived 14 June 1999 and accepted in revised form 16 August
1999.
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0954-6111/00/010076+06 $35?00/0the N-CPAP machine or from reading the eective use
recorded by a pressure monitor coupled with a micro-
processor. The ability of such a monitor to detect residual
apnoeas and to establish a precise diary of eective use, based
on a real-time clock, has received until now little attention.
In the present study we have evaluated compliance with
N-CPAP at home in 106 patients with OSAS. We have used
a pressure monitor which has been shown to accurately
record the eective use of N-CPAP (2). Our objectives were
firstly to search for potential predictors of compliance,
analysing both baseline features of the patients and
variables recorded by the monitor, reflecting the ecacy of
N-CPAP treatment at home, and secondly to take advantage
of the real-time clock included in the monitor to evaluate the
potential influence of sleep habits on compliance.
Methods
STUDY DESIGN
A group of 106 patients prescribed N-CPAP for OSAS
during a 12 month period were selected to study compliance
with domiciliary N-CPAP. All these patients were equipped# 2000 HARCOURT PUBLISHERS LTD
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the eective use of the machine (Rem+ Soft, Sefam,
France). Subjects were instructed to use their machine
nightly and were told that the device included a monitor able
to assess to some extent the ecacy of N-CPAP at home.
PATIENTS
During a 12 month period, a diagnosis of OSAS, with an
apnoea hypopnoea index (AHI)4 20 h71, was made in 134
subjects. This threshold has been considered since 1991 by
the federal authorities in Belgium for reimbursement of N-
CPAP treatment at home. A trial of N-CPAP was made in
the sleep laboratory in 124 subjects, while weight reduction
was preferred in 10 cases. A few patients either required an
auto-CPAP (n= 6) or a ventilatory support system such as
bilevel positive airway pressure (n=2), or refused to try N-
CPAP at home (n=4), or quitted after a few days or weeks
(n=6). The study involved the 106 patients who used
conventional N-CPAP at home for at least 4 months.
SLEEP STUDY
An all night baseline polysomnography was performed
using standard sleep recording leads (electro-oculogram,
electroencephalogram (EEG), chin electromyogram, elec-
trocardiogram (ECG), nasobuccal thermistor, thoracic and
abdominal belts, and transcutaneous oximetry). Sleep
staging was performed according to the criteria of
Rechtschaen and Kales (3). Sleep period time (SPT) was
defined as the time from the onset of sleep to the last
awakening in the morning, and total sleep time (TST) as
SPT minus any time the subject was awake after falling
asleep. Stage shift index (SSI) was the sum of all stage shifts
divided by SPT, expressed as a number h71. Apnoea was
defined as a cessation of flow at the nose and mouth for at
least 10 sec, hypopnoea as a decrease for at least 10 sec in
the amplitude of airflow signal to less than 50% of the level
prevailing before the event, coupled with a fall in
oxyhemoglobin saturation (SaO2) of 3% or more. The
apnoea index (AI), hypopnoea index (HI) and apnoea
hypopnoea index (AHI) were calculated respectively as the
sum of all apnoeas, all hypopnoeas, all apnoeas and
hypopnoeas divided by TST and were expressed as a
number of events h71. Variables retained for analysis in
this study were the AI, HI, AHI, the minimal level (SaO2
min) and mean level (SaO2 mean) of SaO2, the SSI, the
proportion of slow-wave sleep (SWS) and that of rapid eye
movement sleep (REMS), both expressed as a percentage of
SPT. N-CPAP titration was performed in each patient on a
subsequent night in the Sleep Laboratory. The pressure was
individually adjusted to such a level that most apnoeas and
hypopnoeas were abolished and snoring was eliminated.
ASSESSMENT OF COMPLIANCE
Two readings from the time counter and from the pressure
monitor were obtained after 2 and 4 months of N-CPAP
treatment at home, and the third and fourth months oftreatment were retained for analysis. In 49 of the 106
subjects, further readings were made after 6 and 8 months,
in order to evaluate the stability of compliance data. The
pressure monitor is equipped with a microprocessor, an
analogue-to-digital converter, a battery back-up, a real-
time clock and a power-on reset circuit. The variable
component of the pressure signal given by the pressure
transducer is analysed in order to determine whether the
patient is breathing into the mask. Up to 100 consecutive
sessions of treatment can be recorded (a session being
defined as the time from power on to power o). The
pressure monitor yielded the following variables. Mean
eective use per 24 h was defined as the cumulative time of
eective use recorded by the monitor, divided by the
number of days elapsed between the two readings. The
percentage of the monitored days during which the machine
had been eectively used was also available, as well as the
mean eective use per eective day, defined as the
cumulative time of eective use divided by the number of
days the machine had been actually used. The mean
delivered pressure was the arithmetical mean of the
pressures delivered on all sessions, weighted by the duration
of each session. The residual apnoea index was the sum of
all apnoeas identified by the monitor, divided by the
cumulative time of eective use. ‘Short’ apnoeas (between
10 and 20 sec duration) and ‘long’ apnoeas (longer than 20
sec) were evaluated separately. In each subject a printout
was obtained showing the pattern of N-CPAP use at home,
including time of starting with N-CPAP treatment, number
of episodes when the pressure was no longer applied during
the night, time of quitting N-CPAP and presence or not of
naps with N-CPAP. Mean start time on N-CPAP, and its
variability over the 60 days period, was recorded for each
subject. Particular care was taken to change the clocks of
the monitors at dates of shift from winter to summer time.
Periods during which subjects made journeys involving
clock shifts were excluded from the analysis.
STATISTICAL ANALYSIS
Samples were described as mean (standard deviation (SD))
or as median (range) values. Rank correlation was used in a
between-subject analysis to evaluate the relationship
between compliance variables and other variables and,
hence, to search for predictors of compliance. Where the
variables derived from the pressure monitor are concerned,
the values retained for analysis were measured, as
described, on a period of+60 days. Furthermore, a within-
subject linear regression analysis was performed in the last
30 subjects recruited for this study, in order to evaluate the
eect of sleep hygiene on compliance in these individuals.
Results
SUBJECTS
Our sample included 91 men and 15 women. Their
anthropometric features reported as mean (SD) values were:
age 50 (11) years, height 174 (8) cm, weight 1064 (248) kg
78 A. NOSEDA ET AL.and body mass index (BMI) 351 (60) kg m72. As shown in
Table 1, the profile of this group was a severe OSAS with
marked oxyhaemoglobin desaturation and marked sleep
fragmentation.
COMPLIANCE
All compliance variables are reported as median (range)
values. Time counter readings showed that the machines
were on power by 49 (02–92) h per 24 h, while the mean
eective use amounted 45 (02–90) h per 24 h. The patients
used their machine a median of 88% of days (16–100%),
with a mean eective use of 56 (13–112) h per eective
day. As shown in Fig. 1, the % of nights the machine was
used showed a distribution skewed to the left, with 47 of
106 subjects using it 90–100% of nights (among whom 26
subjects using it 100% of nights). The mean delivered
pressure was 81 (40–148) cm H2O, to be compared with aTABLE 1. Results of sleep study in 106 patients with
obstructive sleep apnoea syndrome
AI h71 363 (1–94)
HI h71 231 (6–87)
AHI h71 624 (21–132)
SaO2 min % 680 (37–91)
SaO2 mean % 895 (49–97)
SSI h71 560 (18–122)
SWS % 13 (0–21)
REMS % 99 (0–33)
Values are median (range). For abbreviations see text.
FIG. 1. Histogram of the percentage of days the machine
was used in 106 patients prescribed nasal continuous
airway pressure (N-CPAP) at home for obstructive sleep
apnoea syndrome (OSAS).prescribed pressure of 83 (40–150) cm H2O. Residual
apnoea index recorded by the monitor was 15 (03–
276) h71, with 12 (03–199) h71 apnoeas lasting 10–20
sec and 03 (00–114) h71 apnoeas longer than 20 sec.
Mean clock-time for starting with N-CPAP was 23.54 h
(21.34 h–01.42 h), with marked within-subject variability.
Thirty-one subjects of 106 took diurnal naps on N-CPAP,
with diurnal use of N-CPAP occurring on a median of
51% of days (17–200%). The median duration of naps
was 90 (12–132) min. The remaining 75 subjects took no
naps on N-CPAP.
STABILITY OF COMPLIANCE OVER TIME
In 49 subjects, the mean eective uses over the first, second
and third periods (respectively third/fourth, fifth/sixth,
seventh/eighth months of domiciliary treatment) were 50
(02–91), 49 (02–94) and 48 (03–93) h per 24 h.
Individual patterns showed that compliance was stable in
41 subjects, decreased over time in five subjects and
improved over time in three subjects.
RELATIONSHIP OF COMPLIANCE WITH
OTHER VARIABLES
The various expressions of compliance were daily use
assessed from the time counter, eective use per 24 h,
eective use per eective day and percentage of days the
machine was used. These variables were, as expected,
strongly intercorrelated, the correlation between eective
use per eective day and % of days the machine was used
being, however, markedly weaker (Spearman’s rs=029).
The mean use per eective day and the percentage of days
the machine was used were evaluated against potential
predictors of compliance, including age, BMI, polysomno-
graphic variables (AI, HI, AHI, SaO2 min, SaO2 mean,
SSI, % SWS, % REMS) and variables derived from the
pressure monitor (eective pressure delivered, dierence
between eective and prescribed pressure, residual apnoea
indices, time of starting with N-CPAP and intra-individual
variation in this time). Rank correlation was used in all
cases. As shown in Table 2, the mean eective use per
eective day correlated negatively with SaO2 min and SaO2
mean (both rs= 7024, P5005) and the percentage of
nights the machine was used correlated negatively with the
percentage of SWS (rs=7022, P5005). The relationship
between the mean eective use per eective day and SaO2
min is illustrated in Fig. 2.
COMPLIANCE ANALYSED ON A WITHIN-
SUBJECT BASIS
In a subset of 30 subjects, the within-subject correlation
coecient between start time on N-CPAP on a particular
night and the eective duration of N-CPAP treatment on
that night ranged from +003 to 7070 (median 7048),
with a statistically significant association between early
start on N-CPAP, presumably reflecting early bedtime, and
TABLE 2. Correlation between compliance data and age,
body mass index (BMI), polysomnographic variables and
nasal continuous positive airway pressure (N-CPAP)
monitored variables in 106 N-CPAP users
Mean eective
use per
eective day
% of days
the machine
was used
Age 014 010
BMI 011 009
AI 009 014
HI 013 006
AHI 015 015
SaO2 min 7024* 7014
SaO2 mean 7024* 7014
SSI 009 008
SWS 7015 7022*
REMS 7009 7010
Pressure 001 012
Delta pressure 001 7010
Residual AI 003 001
Start time on N-CPAP 7002 7001
Variability in start time 009 016
Data in the table are Spearman’s rank correlation
coecients. *P5 005.
Pressure = eectively delivered pressure, delta pressure =
dierence between prescribed and delivered pressure.
FIG. 2. Eective use of nasal continuous airway pressure
(N-CPAP) per eective day, expressed in hours, plotted
against SaO2 min at baseline polysomnography, expressed
in %.
FIG. 3. Eective use of nasal continuous airway pressure
(N-CPAP) in a particular subject plotted against start
time on N-CPAP during 60 consecutive days of eective
use. Eective use is expressed in hours, start time in
decimal hours around midnight (e.g. 2045 hours =
7325). This subject was chosen as having the best
correlation coecient (r=7070) among the 30 subjects
studied.
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shown in Fig. 3.
Discussion
In the present study, compliance with N-CPAP at home
was assessed during the third and fourth months of
treatment, using a pressure monitor, in 106 OSAS patients
instructed to use their machine nightly. The subjects used
their device a median of 88% of days, with a median value
of 56 h of mean use per eective day, resulting in a median
value of 49 h of mean use per 24 h.
Compliance with N-CPAP at home has been assessed in
the past using various methods. Self-reported use, obtained
from subject interview, has been shown to overestimate
objective use, assessed from the time counter, by an average
of 10 (4) to 12 (5) h. The discrepancy between mean use
assessed from the time counter and mean eective use
measured with a pressure monitor is smaller, varying
between 04 (6) and 05 (7) h in most studies, yet amounting
10 h in the study by Reeves-Hoche et al. (8). The mean use
per 24 h was found to be in the range 47 (6,7) to 60 (4) h
when assessed using a time counter, 40 (8) to 49 (9) h when
measured using a pressure monitor and was reported as
bimodally distributed in some studies (10,11). As compli-
ance has been reported to be low in some N-CPAP users
during the earliest period of treatment, and high in
80 A. NOSEDA ET AL.chronically treated patients because of selection of long-
term N-CPAP acceptors (2), we chose in the present study
to avoid these particular settings and to evaluate compli-
ance during the third and fourth months of treatment.
Many investigators have found that there is no factor
predicting compliance with domiciliary N-CPAP (5–7,9,11).
A positive correlation with baseline AHI has been reported
in several other studies (4,8,12,13). Other predictors
proposed more occasionally were the amount of improve-
ment in AHI on the acute CPAP trial in the sleep unit (4),
young age (8) and sleep fragmentation at baseline
polysomnography (14). Most of these studies involved
series of less than 100 subjects. Recently, Krieger et al.,
reporting on a large series of 576 N-CPAP users, found that
compliance was positively correlated with baseline AHI,
age and BMI, and negatively with daytime PaO2, forced
expiratory volume in 1 sec (FEV1) and forced vital capacity
(FVC) (13). However, even the highest correlation coe-
cient—that with AHI—was solely 024.
The main originality of the present study is that it reports
on compliance with N-CPAP in terms of two distinct
components, namely the percentage of nights the machine
was used and the mean use per eective day. So doing, we
found that regular use of the machine was associated to
some extent with decreased SWS at baseline polysomno-
graphy, while treatment duration per eective day corre-
lated to some extent with the severity of oxyhaemoglobin
desaturation. The observed correlations were, however, as
in other studies, modest. On clinical ground, the separation
of poorly compliant patients into two groups, those with a
low percentage of use and those with only short use, looks
potentially useful. Indeed, irregular users of the machine
are candidates for some educational intervention such as
attendance to a group clinic (15) or weekly follow-up by
phone calls (16) which have been shown to be eective in
improving compliance. On the other hand, subjects who fall
asleep every night on N-CPAP but use it only for a short
time, because—in most instances—they cannot tolerate it
for a longer period, or because their sleep time is very short,
may require a change to some other N-CPAP modality
such as an auto-CPAP (17,18) or a device aiming to correct
airflow limitation (19), which have been shown to enhance
observance to some extent (18,19), or may benefit from
some pharmacological therapy to lengthen or to stabilize
sleep. In case of failure of this approach, these patients
might also benefit during the second part of the night, when
N-CPAP is o, from some pharmacological agent known to
have a beneficial eect on nocturnal breathing (20).
One of the objectives of the current study was to evaluate
the relationship of some variables recorded by the pressure
monitor with compliance variables. We hypothesized that a
larger discrepancy between the prescribed pressure and the
eective pressure, reflecting leaks and/or repeated use of
the ramp device, would be correlated with lower compli-
ance. Indeed, mouth leaks have been shown to induce an
increase in nasal airway resistance (21), possibly associated
with nasal symptoms, while repeated ramping has been
reported as a form of non compliance (22). Similarly, a
higher index of residual apnoeas, reflecting to some extent a
lower ecacy of N-CPAP treatment, might have an adverseinfluence on compliance. However, despite these expecta-
tions, we were unable to find any significant correlation
between these variables and compliance data.
It has been argued that a pressure monitor is unneces-
sary, as the discrepancy between eective use and ‘power
on’ use per 24 h does not exceed 0.5 h on average (1). We
disagree with this statement, as the pressure monitor allows,
as explained, to make a distinction between ‘irregular users’
and ‘short users’ when the overall use per 24 h is low. The
use of a pressure monitor has an additional advantage, in
that it includes a real clock-time, allowing us to establish a
precise diary of eective use and to study the influence of
sleep habits. Our patients started with N-CPAP on average
at 2254 hours. Provided this time reflected time of
attempting sleep, this finding means that these patients
tried to fall asleep on average 45 min later than the mean
reported time to attempt sleep in a healthy population (23)
and is consistent with the current claim of such patients—in
clinical practice—that the use of N-CPAP decreases
evening fatigue with, as a result, going to bed later than
when they were not treated. Another finding was consistent
with the perception of decreased fatigue, i.e. napping on N-
CPAP was recorded in only 29% of patients, a finding to be
compared with 59% of untreated patients reporting
daytime napping in a study involving subjects with OSAS
of comparable severity (24). However, starting with N-
CPAP earlier correlated with longer duration of treatment
in 22 of 30 individuals when analyzed on a within-subject
basis. Hence, late bedtime should be discouraged in N-
CPAP users, even if patients claim decreased fatigue.
Besides, in healthy subjects, those going to bed earlier have
been reported to show a higher subjective sleep quality and
less mental activity across the night than those going to bed
later (25,26).
In conclusion, compliance with N-CPAP at home,
evaluated using a pressure monitor, contains a component
of regularity, as assessed by the percentage of days the
machine is used, and a distinct component of sleep duration
on N-CPAP, as assessed by the mean eective use per
eective day. The correlations between these two compo-
nents and the baseline features of the patients are modest.
Poorly compliant subjects, irregular users and short
sleepers need distinct interventions. Finally, late bedtime
should be recognized as a potential cause for low
compliance in some N-CPAP users.
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